Itemoids

US

What Happens if Russia Stashes Nukes in Belarus

The Atlantic

www.theatlantic.com › newsletters › archive › 2023 › 05 › what-happens-if-russia-stashes-nukes-in-belarus › 674221

This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here.

The dictator of Belarus, Alexander Lukashenko, has signed an agreement with Russia to base Russian nuclear weapons in his country. The strategic impact of such a move is negligible, but a lot can go wrong with this foolish plan.

First, here are four new stories from The Atlantic:

The play that explains Succession (and everything else) The Russian red line Washington won’t cross—yet. COVID shots are still one giant experiment. AI is unlocking the human brain’s secrets. A Tense Summer

Russia has taken another step toward nuclearizing its satrapy in neighboring Belarus. This is bad news but not a crisis (yet). But first, I want to add a note to what I wrote a few weeks ago about the drone attack on the Kremlin.

I suggested that the weird strike on a Kremlin building was unlikely to be an act sanctioned or carried out by the Ukrainian government. My best guess at the time was that the Russians might be pulling some kind of false-flag stunt to justify more repression and violence against Ukraine as well as internal dissent in Russia. I didn’t think the Ukrainians would attack an empty building in the middle of the night.
The U.S. intelligence community, however, now thinks the strike could have been some kind of Ukrainian special operation. Those same American analysts, according to The New York Times, are not exactly sure who authorized action against the Russian capital:

U.S. intelligence agencies do not know which unit carried out the attack and it was unclear whether President Volodymyr Zelensky of Ukraine or his top officials were aware of the operation, though some officials believe Mr. Zelensky was not.

That’s not much to go on, especially because the intelligence community’s confidence in this view is “low,” meaning there is at least some general, but not specific, evidence for it. The Americans suggest the attack may have been “orchestrated” by the Ukrainian security services, but that could mean any number of possibilities, including civilians, a small militia, a few people loosely affiliated with the Ukrainians, or even a commando team.

The best evidence, however, that this was not a false flag is that with the exception of firing a wave of missiles, the Russian government has said and done almost nothing in response either in Ukraine or in Russia. If Vladimir Putin’s security forces had engineered the incident, they’d almost certainly be taking advantage of it, but they’re not. Instead, the Kremlin seems paralyzed and has clamped down on any further reporting about the whole business; if the Ukrainian goal was to rattle Russian leaders, mission accomplished. So my theory has gone up in smoke—a hazard of trying to piece together an explanation while waiting for better evidence—but I thought it important to update you here.

Now, about those Belarus nukes.

Putin announced back in March that he intended to station nuclear arms in Belarus, a move that had Belarusian President Alexander Lukashenko doing a bit of uneasy throat-clearing as he tried to stay in Putin’s good graces while being understandably nervous about hosting weapons of mass destruction in his fiefdom. The hesitation is over: Belarusian Defense Minister Victor Khrenin and Russian Defense Minister Sergey Shoigu yesterday signed a formal agreement allowing the deployment of Russian nuclear weapons in Belarus.

This would be the first time post-Soviet Russia has stationed nuclear weapons outside its own territory, but the bombs aren’t in Belarus yet. Lukashenko was in Moscow yesterday to attend a summit of the Eurasian Economic Forum, and although he claimed that the complicated process of relocating Russian nuclear bombs has already begun, I don’t believe him. (There I go again, theorizing in the absence of evidence. But Western intelligence agencies watch the movement of Russian nuclear weapons pretty closely, and so far, none of them has indicated that they see anything happening.) Besides, Lukashenko’s assertion wasn’t exactly definitive; when asked in Moscow if the weapons had already arrived, he said, “Maybe. I will go and take a look.”

Now, without getting too far over my skis, I will say that the leaders of countries with nuclear weapons in their territory know without exception whether they have them or not, and don’t need to “go and take a look.” Lukashenko’s flip comment suggests to me that he knows that nothing has been moved yet, and that he understands that his role in this dangerous sideshow is to play along with the Kremlin’s attempt to jangle Western nerves about nuclear war.

Putin, for his part, has said that storage facilities for Russian nuclear arms will be complete by July 1. Nuclear weapons, of course, require highly secure military installations and personnel trained in dealing with such systems, such as how to load them onto their delivery vehicles, and the unique safety precautions that surround them. Even in the best of times, nuclear weapons are a high-maintenance proposition, and accidents do happen: In 2007, an American B-52 flew across the United States with six nuclear bombs that the crew didn’t realize were mounted on the wings.

It’s also possible that Putin is squeezing political impact of a nuclear agreement while he still can, given recent questions about Lukashenko’s health. The Belarus strongman has looked weak lately. It would be very much Putin’s gangland style to make sure he gets Belarus as a stage for his nuclear threats as soon as possible, if he thinks the grim reaper is about to step in.

Putin’s July deadline is also important because it means the Russians will be moving nuclear weapons in the middle of what looks to be a summer of intense fighting. Such a timetable is probably intentional. The Kremlin boss believes that the West is deeply afraid of nuclear war, and he intends to play on that fear. Western leaders, of course, are deeply afraid of nuclear war, because they are not utter psychopaths. Putin and his generals, although brutal and vicious men, are afraid of it, too, no matter what they might say, because they are not suicidal. (So were Soviet leaders and their generals, as we learned after the Cold War.)

What Putin fails to understand, however, is that years of struggling with the Soviet Union taught the United States and its allies how to contend with an aggressive Kremlin and the dangers of escalation at the same time. Putin, as I often note, is a Soviet nostalgist who longs for the old Soviet empire and who still seems to believe that a weak and decadent West will not continue to oppose him.

As ever, I worry not about Putin’s deliberate move to start World War III, but about some kind of error or accident when transferring nuclear weapons from one paranoid authoritarian country to another. Putin may well place nuclear weapons close to Ukraine and then claim that NATO is threatening Russia’s nuclear deterrent, thus provoking a crisis he thinks will induce the West to back away from supporting Kyiv. This would be yet another harebrained blunder in a series of poor moves, but Putin, as we know, is not exactly a master strategist. It’s going to be a tense summer.

Related:

“Lukashenko is easier to unseat than Putin.” The irreversible change in Belarus Today’s News A South Carolina circuit-court judge has temporarily blocked the state’s six-week abortion ban, one day after Governor Henry McMaster signed it into law. A House committee led by Texas Republicans recommended the impeachment of State Attorney General Ken Paxton yesterday, citing years of alleged lawbreaking and misconduct. The Mississippi police officer who shot Aderrien Murry, an unarmed 11-year-old Black boy, has been suspended with pay as the shooting is investigated. Dispatches Work in Progress: The hottest trend in investing is mostly a sham, James Surowiecki writes.

The Books Briefing: Books editor Gal Beckerman breaks down what you should be reading this summer—just in time for the season’s unofficial start.

Explore all of our newsletters here.

Evening Read Carlos Lopez-Calleja / Disney

A Chinese American Show That Doesn’t Bother to Explain Itself

By Shirley Li

Growing up in suburban New Jersey, I dreaded having new visitors over. I wasn’t asocial; I just feared that anyone who wasn’t Chinese—as in, the majority of my classmates—wouldn’t understand my family home and all of its inevitable differences from their own. Even if they didn’t ask me about the cultural objects they might stumble upon around the house, I felt the need to explain what they were seeing, in order to make them comfortable. We have this taped to the wall because it’s the Chinese character for fortune! These hard-boiled eggs are brown because they’ve been soaked in tea! In an attempt to prove that my surroundings were perfectly normal, I turned myself into a tour guide, and my own home into a sideshow.

American Born Chinese doesn’t bother with such disclaimers. The Disney+ show, now streaming, is exuberant and unabashed about its hyper-specific focus on the Chinese American experience.

Read the full article.

More From The Atlantic

Jennifer Egan: Martin Amis taught me how to be funny.

How America can avoid the next debt-ceiling showdown

Ozempic in teens is a mess.

Culture Break Kailey Schwerman / Showtime

Watch. Yellowjackets’ Season 2 finale (streaming on Showtime) made a terrible mistake.

Listen. To the first episode of the newly launched Radio Atlantic podcast with host Hanna Rosin, on whether the war in Ukraine can recapture the world’s attention at a crucial moment.

Play our daily crossword.

P.S.

This is my last Daily for the next week or so, as I am headed off for some sunshine and downtime, but senior editor Isabel Fattal and our colleagues at The Atlantic will keep things as lively here as ever. (This newsletter will be off on Monday for Memorial Day, so look for the next edition on Tuesday.)

With vacation on my mind, I want to recommend a gem of a movie about Las Vegas that has lived in the shadow of Martin Scorsese’s Casino (an undeniable masterpiece) for too long. Twenty years ago, William H. Macy, Maria Bello, and Alec Baldwin starred in The Cooler, one of the bleakest movies about Sin City since Leaving Las Vegas. Macy plays a “cooler,” a guy whose bad luck is so contagious that the casinos hire him to stand near people who win too much money at the tables.

It’s a love story and a crime story, but it’s also about old Vegas becoming a new (and sillier) Vegas. Back then, developers were making an inane attempt to transform an industry mostly devoted to gambling, booze, and sex into a theme park for families. Alec Baldwin—who was nominated for Best Supporting Actor—rails against it all in a rant about the Strip circa 2002: “You mean that Disneyland mook fest out there? Huh? That’s a fucking violation is what that is. Something that used to be beautiful, used to have class, like a gorgeous high-priced hooker with an exclusive clientele … It makes me want to cry, because I remember the way she used to be.”

I cheer him on every time. See you in a few weeks.

— Tom

Katherine Hu contributed to this newsletter.

What Should Go Into This Year’s COVID Vaccine?

The Atlantic

www.theatlantic.com › science › archive › 2023 › 05 › covid-vaccine-strain-xbb1 › 674208

This fall, millions of Americans might be lining up for yet another kind of COVID vaccine:  their first-ever dose that lacks the strain that ignited the pandemic more than three and a half years ago. Unlike the current, bivalent vaccine, which guards against two variants at once, the next one could, like the first version of the shot, have only one main ingredient—the spike protein of the XBB.1 lineage of the Omicron variant, the globe’s current dominant clade.

That plan isn’t yet set. The FDA still has to convene a panel of experts, then is expected to make a final call on autumn’s recipe next month. But several experts told me they hope the agency follows the recent recommendation of a World Health Organization advisory group and focuses the next vaccine only on the strains now circulating.

The switch in strategy—from two variants to one, from original SARS-CoV-2 plus Omicron to XBB.1 alone—would be momentous but wise, experts told me, reflecting the world’s updated understanding of the virus’s evolution and the immune system’s quirks. “It just makes a lot of sense,” said Melanie Ott, the director of the Gladstone Institute of Virology, in San Francisco. XBB.1 is the main coronavirus group circulating today; neither the original variant nor BA.5, the two coronavirus flavors in the bivalent shot, is meaningfully around anymore. And an XBB.1-focused vaccine may give the global population a particularly good shot at broadening immunity.

At the same time, COVID vaccines are still in a sort of beta-testing stage. In the past three-plus years, the virus has spawned countless iterations, many of which have been extremely good at outsmarting us; we humans, meanwhile, are only on our third-ish attempt at designing a vaccine that can keep pace with the pathogen’s evolutionary sprints. And we’re very much still learning about the coronavirus’s capacity for flexibility and change, says Rafi Ahmed, an immunologist at Emory University. By now, it’s long been clear that vaccines are essential for preventing severe disease and death, and that some cadence of boosting is probably necessary to keep the shots’ effectiveness high. But when the virus alters its evolutionary tactics, our vaccination strategy must follow—and experts are still puzzling out how to account for those changes as they select the shots for each year.

In the spring and summer of 2022, the last time the U.S. was mulling on a new vaccine formula, Omicron was still relatively new, and the coronavirus’s evolution seemed very much in flux. The pathogen had spent more than two years erratically slingshotting out Greek-letter variants without an obvious succession plan. Instead of accumulating genetic changes within a single lineage—a more iterative form of evolution, roughly akin to what flu strains do—the coronavirus produced a bunch of distantly related variants that jockeyed for control. Delta was not a direct descendant of Alpha; Omicron was not a Delta offshoot; no one could say with any certainty what would arise next, or when. “We didn’t understand the trajectory,” says Kanta Subbarao, the head of the WHO advisory group convened to make recommendations on COVID vaccines.

And so the experts played it safe. Including an Omicron variant in the shot felt essential, because of how much the virus had changed. But going all in on Omicron seemed too risky—some experts worried that “the virus would flip back,” Subbarao told me, to a variant more similar to Alpha or Delta or something else. As a compromise, several countries, including the United States, went with a combination: half original, half Omicron, in an attempt to reinvigorate OG immunity while laying down new defenses against the circulating strains du jour.

And those shots did bolster preexisting immunity, as boosters should. But they didn’t rouse a fresh set of responses against Omicron to the degree that some experts had hoped they would, Ott told me. Already trained on the ancestral version of the virus, people’s bodies seemed to have gotten a bit myopic—repeatedly reawakening defenses against past variants, at the expense of new ones that might have more potently attacked Omicron. The outcome was never thought to be damaging, Subbarao told me: The bivalent, for instance, still broadened people’s immune responses against SARS-CoV-2 compared with, say, another dose of the original-recipe shot, and was effective at tamping down hospitalization rates. But Ahmed told me that, in retrospect, he thinks an Omicron-only boost might have further revved that already powerful effect.

Going full bore on XBB.1 now could keep the world from falling into that same trap twice. People who get an updated shot with that strain alone would receive only the new, unfamiliar ingredient, allowing the immune system to focus on the fresh material and potentially break out of an ancestral-strain rut. XBB.1’s spike protein also would not be diluted with one from an older variant—a concern Ahmed has with the current bivalent shot. When researchers added Omicron to their vaccine recipes, they didn’t double the total amount of spike protein; they subbed out half of what was there before. That left vaccine recipients with just half the Omicron-focused mRNA they might have gotten had the shot been monovalent, and probably a more lackluster antibody response.

Recent work from the lab of Vineet Menachery, a virologist at the University of Texas Medical Branch, suggests another reason the Omicron half of the shot didn’t pack enough of an immunizing punch. Subvariants from this lineage, including BA.5 and XBB.1, carry at least one mutation that makes their spike protein unstable—to the point where it seems less likely than other versions of the spike protein to stick around for long enough to sufficiently school immune cells. In a bivalent vaccine, in particular, the immune response could end up biased toward non-Omicron ingredients, exacerbating the tendencies of already immunized people to focus their energy on the ancestral strain. For the same reason, a monovalent XBB.1, too, might not deliver the anticipated immunizing dose, Menachery told me. But if people take it (still a big if), and hospitalizations remain low among those up-to-date on their shots, a once-a-year total-strain switch-out might be the choice for next year’s vaccine too.

Dropping the ancestral strain from the vaccine isn’t without risk. The virus could still produce a variant totally different from XBB.1, though that does, at this point, seem unlikely. For a year and a half now, Omicron has endured, and it now has the longest tenure of a single Greek-letter variant since the pandemic’s start. Even the subvariants within the Omicron family seem to be sprouting off each other more predictably; after a long stint of inconsistency, the virus’s shape-shifting now seems “less jumpy,” says Leo Poon, a virologist at the University of Hong Kong. It may be a sign that humans and the virus have reached a détente now that the population is blanketed in a relatively stable layer of immunity. Plus, even if a stray Alpha or Delta descendant were to rise up, the world wouldn’t be caught entirely off guard: So many people have banked protection against those and other past variants that they’d probably still be well buffered against COVID’s worst acute outcomes. (That reassurance doesn’t hold, though, for people who still need primary-series shots, including the kids being born into the world every day. An XBB.1 boost might be a great option for people with preexisting immunity. But a bivalent that can offer more breadth might still be the more risk-averse choice for someone whose immunological slate is blank.)

More vaccination-strategy shifts will undoubtedly come. SARS-CoV-2 is still new to us; so are our shots. But the virus’s evolution, as of late, has been getting a shade more flu-like, and its transmission patterns a touch more seasonal. Regulators in the U.S. have already announced that COVID vaccines will probably be offered each year in the fall—as annual flu shots are. The viruses aren’t at all the same. But as the years progress, the comparison between COVID and flu shots could get more apt still—if, say, the coronavirus also starts to produce multiple, genetically distinct strains that simultaneously circulate. In that case, vaccinating against multiple versions of the virus at once might be the most effective defense.


Flu shots could be a useful template in another way: Although those shots have followed roughly the same guidelines for many years, with experts meeting twice a year to decide whether and how to update each autumn’s vaccine ingredients, they, too, have needed some flexibility. Until 2012, the vaccines were trivalent, containing ingredients that would immunize people against three separate strains at once; now many, including all of the U.S.’s, are quadrivalent—and soon, based on new evidence, researchers may push for those to return to a three-strain recipe. At the same time, flu and COVID vaccines share a major drawback. Our shots’ ingredients are still selected months ahead of when the injections actually reach us—leaving immune systems lagging behind a virus that has, in the interim, sprinted ahead. Until the world has something more universal, our vaccination strategies will have to be reactive, scrambling to play catch-up with these pathogens’ evolutionary whims.

The Russian Red Line Washington Won’t Cross—Yet

The Atlantic

www.theatlantic.com › international › archive › 2023 › 05 › ukraine-us-long-range-missiles-crimea-war-end › 674199

Two months before invading Ukraine, Russia massed more than 100,000 troops on its neighbor’s border and sent NATO a bill of demands. Moscow’s list—structured as a treaty—required that the alliance close itself off to new members. It declared that NATO states “shall not conduct any military activity on the territory of Ukraine as well as other States” in Eastern Europe. It insisted that NATO remove all its forces from the 14 countries that joined after the Soviet Union collapsed. And it asserted that the alliance “shall not deploy land-based” missiles in areas “allowing them to reach the territory” of Russia.

Moscow suggested that the treaty was a pathway for lowering tensions with the West. Yet according to U.S. intelligence officials, Russian President Vladimir Putin had decided to invade Ukraine months earlier. In reality, the treaty was just a diplomatic pretext for the war: a laundry list of things that Putin hated about NATO, wanted changed, and would kill Ukrainians to protest.

But if Putin thought that invading Russia’s neighbor would get the West to accede to his demands, he was wildly mistaken. Rather than pulling troops from its east, NATO responded to Russia’s aggression by deploying more soldiers in Bulgaria, Hungary, Romania, and Slovakia. The alliance did not close its doors; instead, it expanded, adding Finland this April, with Sweden possibly close behind. Ukraine is not part of NATO, but the invasion has pushed the United States and Europe to send remarkable amounts of military assistance to Kyiv, including rockets, tanks, and Soviet-era fighter jets. Most recently, Washington signaled that it will let Europe provide Ukraine with U.S.-made F-16s. The West has effectively flouted all of the draft treaty’s demands.

And yet there’s one line Washington hasn’t crossed. Despite repeated pleas, the United States has not given Kyiv land-based missiles capable of hitting Russia.

“We’re not going to send to Ukraine rocket systems that strike into Russia,” U.S. President Joe Biden told reporters in September. He hasn’t budged since.

Brynn Tannehill: What the drone strikes on the Kremlin reveal about the war in Ukraine

To many analysts, Biden’s decision—and implicit reasoning—is perceptive. Sustained Ukrainian attacks inside Russia’s territory could violate Putin’s red lines in a way that previous strikes haven’t. So could repeatedly hitting Crimea, the peninsula that the Kremlin illegally annexed from Ukraine in 2014. “It’s Crimea and Russian territory,” Austin Carson, a political-science professor at the University of Chicago who studies escalation, told me. “I would worry about crossing one of those bedrock limits.”

But to Ukrainians, these concerns are detached from reality. Kyiv has made isolated attacks on Crimea and Russia before, none of which has widened the conflict. In fact, none of Moscow’s wartime escalations has touched NATO land. And the United Kingdom has already given Kyiv some missiles, fired from planes, that can reach into Russia. France may do so as well. Britain’s provision did not prompt the Kremlin to go berserk.

“People are quite confused,” the former Ukrainian Defense Minister Andriy Zagorodnyuk told me when I asked what Ukrainians thought about Washington’s reticence. “They just don’t understand.”

They are also tremendously frustrated, because Kyiv may need long-range U.S. missiles to win the conflict. “It’s just impossible to be on the battlefield and continuing to fight with the weapons that Ukraine already has,” Polina Beliakova, a Ukrainian political scientist at Dartmouth College who studies civil-military relations, told me. Ukrainian soldiers, she said, are performing admirably. But without superior weapons, even the most motivated military will struggle to defeat a much larger enemy. To liberate more provinces, Ukrainians could have to strike hard, far, and again and again. Washington will have to decide just how much it is prepared to help them.

The United States Army Tactical Missile System is a formidable weapon. Developed in the late Cold War and first used in Operation Desert Storm, ATACMS are launched straight out of the back of vehicles that Washington has already given to Kyiv. (Washington, afraid of escalation, modified the vehicles it sent so that Ukraine couldn’t use them to fire long-range missiles.) Once airborne, the missiles can reach more than three times the speed of sound, making them very difficult to intercept. They can travel up to 186 miles.

These specifications give ATACMS—pronounced “attack-ems”—certain advantages over Britain’s missiles. The latter weapons, although very powerful in their own right, do not move as fast or go quite the same distance as ATACMS. They must be fired out of fighter jets, and Ukraine’s fleet is overtaxed. The radars on Ukrainian jets are also not as powerful as the ones on many Western aircraft, making it tricky for the crew to accurately target each missile. Britain’s provision will become more useful if Kyiv receives F-16s, but Ukrainians won’t be able to fly the U.S. jets for at least several months. And by then, Kyiv may not have many of the missiles left.

“There is no analogue for ATACMS,” Zagorodnyuk told me. “There is no alternative.”

Zagorodnyuk said that, if received, ATACMS could give Ukraine major advantages. For starters, the missiles would make it much easier for Kyiv to hit most of Russia’s command posts and wartime weapons depots, which typically lie beyond the front lines but within 186 miles. ATACMS would also help the Ukrainian military sever the so-called land bridge to Crimea: the thin strip of occupied territory that connects Russia with the peninsula’s isthmus. Similarly, the missiles could hit the bridge that directly links Crimea with Russia. Together, these attacks would substantially weaken Moscow’s forces in southern Ukraine, helping with Kyiv’s counteroffensive. They could even pave the way for Ukraine to take back the peninsula, which is widely considered Kyiv’s hardest military target.

For Ukrainians, taking Crimea may be essential to ending the war and protecting their country, especially given that the peninsula is now a giant staging ground for Russia’s forces. But for Washington, a campaign to take Crimea would be deeply unsettling. Putin views Crimea as perhaps his most prized asset. After Russia seized it in 2014, his approval ratings soared to record highs. The Biden administration has publicly said that Ukraine has the right to liberate all of its occupied territory, Crimea included, yet senior U.S. officials have repeatedly insinuated that going after the peninsula would be too dangerous. In February, for example, U.S. Secretary of State Antony Blinken told experts that an operation for Crimea would be a “red line” for the Kremlin.

In theory, the United States could provide ATACMS on the condition that Ukraine not use them to hit the peninsula. But Kyiv is unlikely to accept such an arrangement. “That would set a massive precedent of treating Crimea as a special case, and that’s exactly what the Russians want,” Zagorodnyuk told me. Ukraine could even be tempted to use the missiles to strike Russia proper. According to The Washington Post, Ukrainian President Volodymyr Zelensky privately proposed attacking Russian villages in order to gain leverage over the Kremlin. And on Monday, pro-Ukrainian militias launched an assault across Russia’s border. They appear to have used U.S.-made vehicles in their incursion.

Publicly, Kyiv has assured Washington that it will not hit Russia with U.S. rockets. But no matter the conditions, guaranteeing that the missiles would not cross one of Moscow’s trip wires is impossible.

“The risk is that you think you’re okay and then you hit that red line and then things escalate really fast out of control,” Jennifer Kavanagh, a senior fellow at the Carnegie Endowment for International Peace, told me. In the worst-case scenario, that spiral could lead to Russia using nuclear weapons. But Kavanagh pointed out that Moscow could escalate in many ways without going nuclear. It could, for instance, carpet-bomb Ukrainian cities. It could also launch cyberattacks on NATO states.

From the June 2023 issue: The counteroffensive

The odds of Russia attacking NATO, digitally or otherwise, might seem long. But they are not outlandish, especially considering Moscow’s perspective. “Russia doesn’t see itself fighting Ukraine,” Margarita Konaev, the deputy director of analysis at Georgetown University’s Center for Security and Emerging Technology, told me. “It sees itself fighting NATO.”

The Kremlin’s reasoning, she explained, makes some sense. Moscow is battling against NATO weapons systems. Its troops are being hit with NATO members’ ammunition. Ukraine is operating based off U.S. intelligence. “The only thing they’re not fighting are NATO troops on the ground,” Konaev said. If Ukraine begins regularly shelling Crimea or Russian territory with U.S.-made weapons, Russia could respond as if NATO was attacking the homeland.

Almost no one knows exactly how many soldiers Ukraine has lost fighting against Russia. But the number is large. According to the classified documents leaked on Discord last month, the U.S. government estimates that Ukraine has suffered somewhere from 124,500 to 131,000 casualties. The figure is lower than Russia’s estimated 189,500 to 223,000 casualties, but Ukraine’s population is about a third the size of its adversary’s. If the war turns into a pure battle of attrition, Kyiv will struggle to hold out.

It’s not surprising, then, that Ukrainians have little patience for Washington’s escalation concerns.

“Not providing better weapons would basically throw Ukraine under the bus in slow motion,” said Beliakova. She described the frustration of sitting through meetings where Western policy makers theorized about what a long war would look like, and how they can help sustain Kyiv. “They go, ‘Oh, well the West can easily supplement this, supplement that, provide this, provide that,’” Beliakova said. “I’m like, ‘Ukraine will run out of people!’” The country, she told me, needs more long-range weapons if it is going to overcome Russia’s enormous demographic advantage.

Some analysts went even further, wondering if Washington’s reluctance was designed to stop Ukraine from winning. “If you’ve noticed, the [Department of Defense], the White House, they never talk about victory,” Zagorodnyuk told me. “They’re still talking about an unknown ending to this story. And so the political goal of the Western coalition is unclear.”

Giving long-range missiles to Kyiv, he said, would help eliminate the ambiguity. Doing so would be a boost to Ukrainian morale—one that might be needed if the forthcoming counteroffensive does not succeed. Providing ATACMS would also signal to the rest of the Western alliance that the United States supports going to the max to help Kyiv, possibly easing hesitations in European capitals about supplying other Ukrainian needs.

Ukrainians do not think that Russia would escalate if the United States sent long-range missiles. “I don’t believe the escalation story,” Zagorodnyuk told me. “There have been tons of other weapons supplied for tens of billions of dollars. ATACMS is not going to make a big difference.” Even if it did prompt Russian anger, Ukrainians are unsure as to why NATO should care. Moscow has escalated in the past: it responded to Kyiv’s astonishingly successful counteroffensive in Kharkiv by mobilizing 300,000 new troops, and it began indiscriminately bombing Ukrainian cities after an explosion damaged the Crimean-Russian bridge. But these steps hurt Ukrainians, not NATO members. Unless Russia uses a nuclear weapon, breaking a nearly 78-year taboo and endangering the entire planet, the West is unlikely to directly enter the conflict because of Russia’s atrocities. And so long as they believe they can win, Ukrainians appear prepared to endure a whole lot.

The country’s hawks have grown pessimistic about getting the missiles. Yes, they said, Washington and its allies have changed their mind in the past. But with tanks and F-16s, Western claims were as much about technical concerns as they were about the security risks. These weapons, policy makers argued, would take too much time and energy for Ukrainians to receive and learn how to use. There are technical risks with ATACMS too: Many American experts worry about depleting the United States’ limited supply, or that Russia could capture a missile, copy its design, and send China a mock-up.

Still, such hurdles can be overcome. Ukraine’s battlefield performance, and its success in Western training programs, helped convince NATO states that the country could handle more sophisticated weapons. If Ukrainians use Britain’s long-range missiles successfully, and in ways the U.S. approves of, Kyiv could convince Washington that it should get ATACMS as well.

But not if Washington is too afraid of how Russia will respond.

“With ATACMS, I don’t see these coming,” Zagorodnyuk said. Then he paused. “Yet.”

The percentage of Americans skipping medical care because of cost is back at pre-Obamacare levels

Quartz

qz.com › more-americans-skipping-medical-care-because-of-cost-1850475244

More Americans than ever before had health insurance coverage in 2022, thanks to Medicaid’s continuous enrollment, a feature of the covid emergency. And yet at the same time, 28% of people in the US chose to skip medical care due to costs—the highest percentage since Obamacare, or Affordable Care Act, became…

Read more...